Researchers have recently presented promising clinical data at the International Society for Stem Cell Research demonstrating that transplanted human neural progenitor cells survived for at least one year in participants with Retinitis Pigmentosa (RP).
News
The latest news from Retina UK. Please use the filters to find the articles which interest you.
Catherine L’Estrange, aged 11 from London has become the first individual in the UK to receive an investigative gene therapy treatment for retinal dystrophy associated with the BBS10 gene.
Octant, a clinical stage drug discovery company, has recently announced the dosing of the first healthy volunteer in their Phase 1a clinical trial of OCT-980 for Rhodopsin-associated autosomal dominant Retinitis Pigmentosa (RHO-adRP).
Biotechnology company Ocugen has announced the enrolment completion of their phase 3 clinical trial for OCU400.
Ocugen have recently announced that they have completed enrolment and dosing in their pivotal phase 2/3 trial of OCU410ST ahead of schedule.
The clinical trial team at The Retina Clinic London have asked us to share an opportunity to participate in a Phase 1 clinical trial for AAVB 039 for Stargardt Disease.
A new study by researchers from Radboud University Medical Centre and the University of Basel has uncovered new genetic causes of Retinitis Pigmentosa (RP) that were once overlooked.
Formal notice of the forthcoming Annual General Meeting in July 2026.
Researchers from Ghent University have published a study that has the potential to transform inherited retinal disease (IRD) treatment development.